Parallax Volatility Advisers’s Lifecore Biomedical LFCR Stock Holding History

Parallax Volatility Advisers’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,158	Closed	-$52K	–	3386
2017 Q4	$52K	Buy	+4,158	New	+$52.5K	﹤0.01%	3211
2017 Q2	–	Sell	-254	Closed	-$3K	–	3213
2017 Q1	$3K	Buy	+254	New	+$3.22K	﹤0.01%	3360
2016 Q4	–	Sell	-9,860	Closed	-$132K	–	3689
2016 Q3	$132K	Sell	9,860 -15,630	-61%	-$189K	﹤0.01%	1998
2016 Q2	$274K	Buy	+25,490	New	+$281K	﹤0.01%	1687
2015 Q1	–	Sell	-231	Closed	-$3K	–	5023
2014 Q4	$3K	Buy	+231	New	+$2.98K	﹤0.01%	4885

Other funds holding LFCR

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Parallax Volatility Advisers's LFCR Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Lifecore Biomedical (LFCR) in Q1 2018, closing a stake of 4,158 shares — an estimated $52K sold.

Parallax Volatility Advisers first reported a position in LFCR in Q4 2014 and held it in 5 quarters. The position peaked at $274K in Q2 2016. 89 funds tracked by Wall St. Rank hold LFCR as of Q1 2018.

Parallax Volatility Advisers reported no remaining Lifecore Biomedical position as of Q1 2018 after selling out during the quarter.
Parallax Volatility Advisers sold 4,158 Lifecore Biomedical shares in Q1 2018, an estimated $52K.
Parallax Volatility Advisers first reported a position in Lifecore Biomedical in Q4 2014 and held it in 5 quarters.
Parallax Volatility Advisers's Lifecore Biomedical position peaked at $274K in Q2 2016.
89 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.